Catalyst Pharmaceuticals ... (CPRX)
22.10
-0.43 (-1.91%)
At close: Feb 20, 2025, 3:59 PM
22.05
-0.23%
After-hours: Feb 20, 2025, 04:37 PM EST
undefined% (undefined)
| Bid | 22.05 |
| Market Cap | 2.64B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.18 |
| PE Ratio (ttm) | 18.73 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 22.17 |
| Volume | 583,938 |
| Avg. Volume (20D) | 1,064,974 |
| Open | 22.39 |
| Previous Close | 22.53 |
| Day's Range | 21.96 - 22.55 |
| 52-Week Range | 13.49 - 24.64 |
| Beta | undefined |
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develop...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2006
Employees 167
Stock Exchange NASDAQ
Ticker Symbol CPRX
Website https://www.catalystpharma.com
Analyst Forecast
According to 8 analyst ratings, the average rating for CPRX stock is "Buy." The 12-month stock price forecast is $32.5, which is an increase of 47.05% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Catalyst Pharmaceuticals Inc. is scheduled to release its earnings on Feb 26, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
+12.75%
Catalyst Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
